Biotechnology stocks tend to be risky, but some are backed by real products and solid earnings, writes Phil van Doorn.
MarketWatch.com - Top Stories, MarketWatch
Fri, 02/27/2015 - 6:29am
Biotechnology stocks tend to be risky, but some are backed by real products and solid earnings, writes Phil van Doorn.